In the group of 69 patients with ER-positive/HER2-negative tumours, they have found that both time to first progression (TTP) and 2 year overall survival (OS) time were shorter for the patients with high-risk RS values (≥ 31) and who received first line endocrine therapy. This evidence concerns the gene ERBB2 and neoplasm.